Skinbiotherap. Regulatory News (SBTX)

SkinBioTherapeutics plc ("SkinBioTherapeutics" or the "Group" or the "Company")

FY Trading Update

14 August 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, announces its trading update for the 12 months to 30 June 2025 (FY25).

Management expects to report unaudited revenues of between c.£4.5m-£4.8m1 (FY24: £1.2m), driven by a full year's trading by Dermatonics, eight months trading by Bio-Tech Solutions (BTS), as well as ongoing growth of organic sales of AxisBiotix. Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end.

Management expects unaudited adjusted EBITDA loss of between c.£0.2m- £0.4m1 (FY24: loss £2.2m) due to careful cost control.

Cash as at 30 June 2025 is better than expectations at £4.8m1 (31 Dec 2024: £1.2m) reflecting the June 2025 Placing and WRAP Retail Offer of £4.2m (gross) to support the exclusive commercial agreement with Superdrug Stores plc ('Superdrug') related to AxisBiotix™ food supplements. Prior to the year-end the Company began incurring costs in preparation for the initial Superdrug launch; the cash at the period end reflects this expenditure.

The above figures are subject to review by the Company's auditors before publication of the final FY25 results later in the year.

Post year end, July was a strong month with significant orders and good trading across the board, especially for the BTS business. Operationally, the team is busy preparing for the launch of AxisBiotix™ in Superdrug stores in the Autumn and is on track.

SkinBioTherapeutics records its revenues under regulatory accounting rule FRS 102 and will continue to segment it geographically as before in its published accounts. Given the competitiveness of the industries that SkinBioTherapeutics operates in, the Company will not divulge information on individual customer sales or provide guidance beyond what is required by disclosure rules. Shareholders are respectfully requested not to contact the Company's customers or partners for additional information as it may harm ongoing and future relationships.

Stuart Ashman, CEO of SkinBioTherapeutics plc, said:

"The past 12 months have marked a distinct change in the operations of the Company, driven by two acquisitions, the launch of Zenakine™ by Croda and the signing of a significant commercial deal with Superdrug to launch AxisBiotix™ on the UK high street. Financially, we are also in a very different place, achieving c.4x the revenues relative to 2024, nearing profitability and have a strong cash balance. Compared to where we were only five years ago, where our majority focus was around research and development, we have come a long way. We strongly believe that the increased interest by consumers and the marketplace in the role of the microbiome on our skin health means that we are very well placed to scale rapidly and achieve significant value for shareholders."

The Company will be reporting its full year results later in the year and will hold a presentation for shareholders at that time. In the meantime, it will report any material information and information of potential interest to shareholders via the RNS system. For information on its operations and products, please visit the individual websites, Dermatonics, Bio-Tech Solutions and AxisBiotix or the Company's LinkedIn HERE.

Footnote

1. The Company considers market expectations prior to the release of this announcement for the year ending 30 June 2025 to be revenue of £5.1m, Adjusted EBITDA of £0.3m loss and cash of £4.1m.

-Ends-

For more information please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of inflammatory skin conditions, is sold directly and via Amazon, and will be sold via an exclusive UK commercial deal with Superdrug Stores plc later in 2025.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.